Nicklesh Thakur, DO
Neurological Surgery · Sacramento, CANPI 1801917554
Payments from drug & device makers
Across 46 payments — averaging $526.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Acadia Pharmaceuticals Inc$17K
- Acorda Therapeutics, Inc$2K
- Sunovion Pharmaceuticals Inc.$2K
- Amneal Pharmaceuticals LLC$2K
- AbbVie$591
- Abbott$244
- plus $833 from 8 others
Across 9 payments — averaging $217.13 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Acadia Pharmaceuticals Inc$2K
What the payments were for
- Consulting fees$4,99049%
- Speaking & faculty fees$3,47534%
- Travel & lodging$140%
- Food & beverage$1,67416%
- Education$851%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Acadia Pharmaceuticals Inc | 6 | $16,603 |
| Acorda Therapeutics, Inc | 1 | $2,275 |
| Sunovion Pharmaceuticals Inc. | 1 | $2,075 |
| Amneal Pharmaceuticals LLC | 4 | $1,618 |
| AbbVie | 15 | $591 |
| Abbott | 6 | $244 |
| Medtronic | 3 | $220 |
| Boston Scientific | 3 | $187 |
| Insightec,inc | 1 | $146 |
| Kyowa Kirin, Inc. | 1 | $119 |
| Merz Pharmaceuticals, LLC | 2 | $64 |
| Teva Pharmaceuticals USA, Inc. | 1 | $60 |
| Revance Therapeutics, Inc. | 1 | $25 |
| Almatica Pharma LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$24,238 in reported general payments places this provider in the 70th percentile of 773 neurological surgery providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 50 | $406,456 |
| RytaryCarbidopa/Levodopa | 287 | $286,978 |
| GocovriAmantadine Hcl | 74 | $236,684 |
| InbrijaLevodopa | 80 | $223,014 |
| BotoxOnabotulinumtoxina | 104 | $182,152 |
| NuplazidPimavanserin Tartrate | 29 | $174,978 |
| NourianzIstradefylline | 59 | $132,356 |
| Carbidopa-LevodopaCarbidopa/Levodopa | 1,111 | $44,702 |
| XadagoSafinamide Mesylate | 16 | $39,020 |
| HorizantGabapentin Enacarbil | 35 | $36,566 |
| Nurtec OdtRimegepant Sulfate | 23 | $30,338 |
| UbrelvyUbrogepant | 29 | $30,182 |
| Carbidopa-Levodopa ErCarbidopa/Levodopa | 534 | $26,814 |
| Rasagiline Mesylate | 96 | $23,103 |
| OngentysOpicapone | 18 | $20,324 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Amneal Pharmaceuticals LLCRytary, Pyridostigmine Bromide | $1,618 | $290,864345 claims |
| Acorda Therapeutics, IncInbrija | $2,275 | $223,01480 claims |
| AbbVieBotox, Ubrelvy | $591 | $212,334133 claims |
| Acadia Pharmaceuticals IncNuplazid | $16,603 | $174,97829 claims |
| Kyowa Kirin, Inc.Nourianz | $119 | $132,35659 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 773 neurological surgery providers in California.
Other neurological surgery in Sacramento
- Kee KimSacramento$2M
- Geoffrey ManleySan Francisco$24.9M
- Christopher AmesSan Francisco$7.1M
- Jamshid SalehRedding$4.1M
- Bruce McCormackSan Francisco$3.9M
- Andrew SchreiberSanta Ana$3.9M
- Larry KhooLos Angeles$3M
- Jennie TaylorSan Francisco$2.7M
- Joseph CiacciSan Diego$2.6M
- Nicholas ButowskiSan Francisco$2.4M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.